Involvement of CD161+ Vδ1+ γδ T cells in systemic sclerosis: Association with interstitial pneumonia

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2259-2269

  Segawa, Seiji ^a   Goto, Daisuke ^a   Horikoshi, Masanobu ^a   Kondo, Yuya ^a   Umeda, Naoto ^a   Hagiwara, Shinnya ^a   Yokosawa, Masahiro ^a   Hirota, Tomoya ^a   Miki, Haruka ^a   Tsuboi, Hiroto ^a   Ogishima, Hiroshi ^a   Suzuki, Takeshi ^a   Matsumoto, Isao ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CCL3; CD161; Gamma delta T cell; Interferon ; Interstitial pneumonia; KL 6; Natural killer receptors; Systemic sclerosis

Indexed keywords

CARBOHYDRATE ANTIGEN; CD161 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSESSMENT; DNA MICROARRAY; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INTERSTITIAL PNEUMONIA; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPERNATANT; SYSTEMIC SCLEROSIS; TH1 CELL;

EID: 84925223012     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu246     Document Type: Article

References (41)

1. Khalil N, O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ 2004;171:153-60.
2. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005;172:268-79.
3. Luna MA, Bedrossian CW, Lichtiger B et al. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972;58:501-10.
4. Poccia F, Gougeon ML, Bonneville M et al. Innate T-cell immunity to nonpeptidic antigens. Immunol Today 1998; 19:253-6.
5. Parker CM, Groh V, Band H et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med 1990;171:1597-612.
6. Das H, Sugita M, Brenner MB. Mechanisms of Vd1 γδ T cell activation by microbial components. J Immunol 2004; 172:6578-86.
7. De Rosa SC, Andrus JP, Perfetto SP et al. Ontogeny of γδ T cells in humans. J Immunol 2004;172:1637-45.
8. Holtmeier W, Witthoft T, Hennemann A et al. The TCRdelta repertoire in human intestine undergoes characteristic changes during fetal to adult development. J Immunol 1997;158:5632-41.
9. Kamath AB, Wang L, Das H et al. Antigens in teabeverage prime human Vg2Vd2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 2003;100: 6009-14.
10. Ramirez A, Varga J. Pulmonary Arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004;3:339-52.
11. Holcombe RF, Baethge BA, Wolf RE et al. Natural killer cells and gamma delta T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. Ann Rheum Dis 1995;54:69-72.
12. Bendersky A, Markovits N, Bank I. Vg9+ γδ T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis. Immunobiology 2010;215:380-94.
13. Braun RK, Ferrick C, Neubauer P et al. IL-17 producing γδ T cells are required for a controlled inflammatory response after bleomycin-induced lung injury. Inflammation 2008; 31:167-79.
14. Simonian PL, Wehrmann F, Roark CL et al. γδT cells protect against lung fibrosis via IL-22. J Exp Med 2010;207: 2239-53.
15. Simonian PL, Roark CL, Diaz del Valle F et al. Regulatory role of γδ T cells in the recruitment of CD4+ and CD8+ T cells to lung and subsequent pulmonary fibrosis. J Immunol 2006;177:4436-43.
16. Segawa S, Goto D, Yoshiga Y et al. Involvement of NK 1.1-positive γδT cells in interleukin-18 plus interleukin-2- induced interstitial lung disease. Am J Respir Cell Mol Biol 2011;45:659-66.
17. Lanier LL, Chang C, Phillips JH. Human NKR-P1A. A disulfide- linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417-28.
18. Fenoglio D, Poggi A, Catellani S et al. Vd1 T lymphocytes producing IFN-g and IL-17 are expanded in HIV- 1-infected patients and respond to Candida albicans. Blood 2009;113:6611-8.
19. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
20. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
23. Poggi A, Zocchi MR, Carosio R et al. Transendothelial migratory pathways of Vd1+ TCRγδ+ and Vd2+ TCRγδ+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J Immunol 2002; 168:6071-7.
24. Catellani S, Poggi A, Bruzzone A et al. Expansion of Vd1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 2007;109:2078-85.
25. Gu YS, Kong J, Cheema GS et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38: 132-60.
26. Giacomelli R, Matucci-Cerinic M, Cipriani P et al. Circulating Vd1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998;41:327-34.
27. Sato S, Nagaoka T, Hasegawa M et al. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000; 200:196-201.
28. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61.
29. Caccamo N, La Mendola C, Orlando V et al. Differentiation, phenotype, and function of interleukin-17- producing human Vg9Vd2 T cells. Blood 2011;118:129-38.
30. Scharffetter K, Heckmann M, Hatamochi A et al. Synergistic effect of tumor necrosis factor-a and interferon- g on collagen synthesis of human skin fibroblasts in vitro. Exp Cell Res 1989;181:409-19.
31. Atamas SP. Complex cytokine regulation of tissue fibrosis. Life Sci 2002;72:631-43.
32. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis. Curr Opin Rheumatol 2002;14:671-80.
33. Koch AE, Kunkel SL, Harlow LA et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994;93:921-8.
34. Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012; 42:281-96.
35. Standiford TJ, Rolfe MW, Kunkel SL et al. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol 1993;151:2852-63.
36. Bolster MB, Ludwicka A, Sutherland SE et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40:743-51.
37. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a) and MIP- 1b) in patients with systemic sclerosis: MCP-1 and MIP-1a may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
38. Zhang Y, McCormick LL, Desai SR et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168: 3088-98.
39. Ishida Y, Kimura A, Kondo T et al. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am J Pathol 2007;170:843-54.
40. Segawa S, Goto D, Yoshiga Y et al. Inhibition of transforming growth factor-beta signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice. Clin Exp Immunol 2010;160:394-402.
41. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002;14:681-5.